Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated August 9, 2004, reports the provisional results of its public offers to acquire Aventis. The filing covers the expiration of the French, German, and U.S. offers and outlines the next steps for the transaction, including the expected announcement of definitive results by the French Autorite des marches financiers (AMF) on August 12, 2004.
Key Financial Metrics and Transaction Data
The filing focuses on the tender statistics for the acquisition rather than standard operating financial metrics such as revenue or profit. Key transaction figures include:
- Total Shares Tendered: 769,920,773 Aventis shares (including underlying ADSs).
- Ownership Percentage (Issued/Outstanding): 95.47% of share capital and 95.52% of voting rights.
- Ownership Percentage (Fully Diluted): 89.84% of share capital and 89.88% of voting rights.
- Warrants Tendered: 92,692 warrants issued in 2002 and 164,556 warrants issued in 2003.
- Settlement Dates: Expected August 20, 2004, for ordinary shares and no later than August 26, 2004, for U.S. ADSs.
The filing text does not provide clear values for Sanofi-Synthelabo's revenue, profit, cash flow, margins, debt, or liquidity for this period.
Material Changes and Transaction Status
The primary material change is the successful tendering of Aventis shares exceeding the minimum threshold required for the offers to be deemed successful. The provisional results indicate that the minimum tender condition will be satisfied pending confirmation by the AMF. The filing notes that the offers were oversubscribed, which may necessitate allocation and proration between the all-cash and all-stock election options.
Guidance, Outlook, and Risks
Outlook and Next Steps: Sanofi-Synthelabo intends to provide a subsequent offering period of at least 10 French trading days if the definitive results confirm the provisional data. The timing for this period is expected to be published on or about August 12, 2004.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Ability to expand profitably in the United States.
- Success of research and development programs.
- Protection of intellectual property rights.
- Risks associated with healthcare cost reimbursement and pricing reforms in the U.S. and Europe.
Unusual Items: The transaction involves a complex mix-and-match election structure for shareholders, requiring potential proration due to oversubscription.
Important Facts for Investor Verification
- Confirmation of the definitive results by the AMF on August 12, 2004.
- The final allocation and proration details resulting from the oversubscription of cash or stock elections.
- The exact timing and terms of the subsequent offering period.
- Completion of the settlement and delivery of consideration by the expected dates (August 20 and August 26, 2004).